Analysis of infective complications during the program chemotherapy of Acute lymphoblastic leukemia in children in Ukraine

Authors

  • Olga Troyanovska Lviv Regional Specialized Childrens Clinic
  • Sergiy Nyankovsky Lviv National Medical University
  • Volodymyr Loginskiy Lviv Institute of blood pathology and transfusion medicine
  • Leonid Dubey Lviv Institute of blood pathology and transfusion medicine

Keywords:

acute lymphoblastic leukemia in chjldren, cellular and humoral immunity, neutropenia, program chemotherapy, infective complications

Abstract

Establishment of intensive chemotherapeutic regimens for the treatment of acute lymphoblastic leukemia /ALL/ in children in Ukraine have led to improved survival of patients. Because the main cause of mortality of children with ALL are life-threatening infective complications, we have assessed the regularity of development of severe infectious diseases during the program chemotherapy and their relation with explored changes of cellular and humoral immunity and neutropenia.

Downloads

Download data is not yet available.

References

Radwanska U., Bialaczki u dzieci,Wroclaw,1998; 17.

Rybalska A., The condition of immune system in patients suffered from acute leukemia with infective complications, Doctor. 2005; 7; 31.

Kubalya N., Drozdova V., Moroz E., The results of childhood ALL treatment according to the modified regimen ALL-BFM-95in the Hematological Department „OHMATDYT”, Ukrainian Journal of Hematology 2003; 2; 40.

Bagirova N., Etiology of infective complications and rational approaches to their treatment in the course of leukemia, Problems of Hematology 2004; 4; 44.

Bondaruk O., Ponamarova O., Klitnyuk G., Prevention and treatment of infective complications of cytotoxic therapy, Ukrainian chemotherapeutic Journal 2005; 1; 21.

Bagirova N., Dmitrieva N., Septicemia in patients with hemoblastosis, Problems of hematology 2002; 4; 21.

Alehina L., Klyasova G., Petrova N., Fungemia in patients with oncohematological diseases, Problems of hematology 2002; 1; 39.

Fedorovska O., Tretyak N., Hemyrovska L., Mycotic complications in patients with acute and chronic leukemias, Ukrainian Journal of hematology and transfusiology, 2003; 6; 17.

Klimenko N., Diagnosis and treatment of invasive aspergillosis, Problems of hematology 2000; 4; 50.

Boyko Ya., Clinical and immunological features of children with acute lymphoblastic leukemia and chronic hepatitis B,C, Oncology. 2000; 2; 80.

Savchenko V., Troitskaya V., Misyurin A., Cytomegaloviral infections in patients with hemoblastosis, Therapeutic archive 2003; 7; 53.

Arico M., Maggiore G., Silini E., Hepatitis C virus infection in children treated for acute lymphoblastic leukemia, Blood. 1995; 9; 2919.

Fattet S., Cassinotti P., Popovic M., Persistent human parvovirus B19 infection in children under maintenance chemotherapy for acute lymphoblastic leukemia, Journal of Pediatric Hematology/Oncology 2004; 8; 497.

Seterynska B., Marianska A., Szczepinska M., Bacterial infections in patients with neutropenia, Acta Haematologica Polonica 2001; 2; 480.

Aleynikova O., Buglova S., Mygal N., Development of immunosuppression in children with acute lymphoblastic leukemia under the intensive chemotherapy regimen, Hematology and transfusiology 2002; 4; 14.

Vladimirskaya E., Kaznacheyev K., Osipova E., Late myelosuppression of chemotherapy regimens in the course of childhood acute lymphoblastic leukemia, Hematology and transfusiology 2000; 1; 6.

Crystal L., T-cell immunodeficiency following cytotoxic antineoplastic therapy, The Oncologist 1999; 4; 370.

Arce Casas A. Humoral immunity in pediatric patients with acute lymphoblastic leukemia, Allergology Immunology. 2003; 6; 303.

Luczynsky W., Stasiak-Barmuta A., Immunologic monitoring of maintenance therapy for acute lymphoblastic leukemia in children – preliminary report, Pediatric Blood Cancer. 2994; 5; 416.

Luczynsky W., Stasiak-Barmuta A., Is cellular immunity not impaired after remission induction in acute lymphoblastic leukemia in children, Polski Merkuriush Lekarski 2004; 91; 17.

Luczynsky W., Stasiak-Barmuta et all.. Immunologic monitoring in children with acute lymphoblastic leukemia during maintenance treatment with regard to co-existing infections. Wiadomosci Lekarski 2004; 7; 337.

Romanski A., Bug G., Becker S., Mechanism of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia, Experimental Hematology 2005; 3; 344.

Haining W., Neuberg D., et all. Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia, Blood 2005; 26; 3720.

Mustafa Mahmount M., Immune recovery in children with malignancy after cessation of chemotherapy, Journal of Pediatric Hematology/Oncology 1998; 5; 451.

Luczynsky W., Stasiak-Barmuta A., Analysis of immune system in children with ALL during maintenance treatment, Acta Haematologica Polonica. 2001; 2; 108.

Schuster F., Moelter C, Schmidt I, et all.Successful antifungal combination therapy with voriconazole and caspofungin, Pediatric Blood Cancer 2005; 7; 682.

Guseva S., Intravenous immunoglobulin use in the practis of hematologists, Ukrainian Journal of Hematology and transfusiology, 2002;4; 60.

BruslovaK., Kutcher O., Prophylaxis of infective complications in children with acute leukemia using i.v. Immunoglobulin, Ukrainian Journal of Hematology, 2004; 3; 35.

Downloads

Published

2006-06-30

How to Cite

Troyanovska, O., Nyankovsky, S., Loginskiy, V., & Dubey, L. (2006). Analysis of infective complications during the program chemotherapy of Acute lymphoblastic leukemia in children in Ukraine. European Journal of Clinical and Experimental Medicine, 4(2), 143–145. Retrieved from https://journals.ur.edu.pl/ejcem/article/view/13412

Issue

Vol. 4 No. 2 (2006): Medical Journal of the Rzeszow University

Section

ORIGINAL PAPERS

License

Copyright (c) 2006 Medical Journal of the Rzeszow University

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.